Adaptation of a mutual exclusivity framework to identify driver mutations within oncogenic pathways.

Abstract excerpt

Distinguishing genomic alterations in cancer-associated genes that have functional impact on tumor growth and disease progression from the ones that are passengers and confer no fitness advantage have important clinical implications. Evidence-based methods for nominating drivers are limited by existing knowledge on the oncogenic effects and therapeutic benefits of specific variants from clinical trials or...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Algorithms
• Share to Computational Biology
• Share to Genomics